Meeting
2022 ASCO Annual Meeting
A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST Study Cohort B.
Authors
Neal D. Shore
Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Thomas Powles , Jens Bedke , Matt D. Galsky , Evgeny Kopyltsov , Andrea Necchi , Joan Palou , Jennifer J. Vermette , Alison E. Randall , Kristen J. Pierce , Rossano Cesari , Gary D. Steinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04165317
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4614)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4614
Abstract #
TPS4614
Poster Bd #
97a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
First Author: Ashish M. Kamat
Poster
2019 Genitourinary Cancers Symposium
Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
First Author: Ashish M. Kamat
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
First Author: Maria De Santis
Poster
2016 ASCO Annual Meeting
KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).
First Author: Ashish M. Kamat